1. Pseudophakic macular edema in nondiabetic and diabetic patients without diabetic retinopathy treated with intravitreal dexamethasone implant
- Author
-
Magna Vanessa Rodrigues, Jose Mauricio Botto Garcia, Katia Delalibera Pacheco, Fabricio Tadeu Borges, David Leonardo Cruvinel Isaac, and Marcos Avila
- Subjects
Dexamethasone ,Intravitreal injections ,Macular edema ,Cataract ,Phacoemulsification ,Ophthalmology ,RE1-994 - Abstract
Abstract Background The purpose of this study was to compare the impact of intravitreal dexamethasone (DEX) implant during a 12-month period in nondiabetic and diabetic patients without diabetic retinopathy (DR) as a treatment for refractory pseudophakic cystoid macular edema (PCME) following prior treatment with topical nepafenac 0.1% and prednisolone 1%. Methods Forty-two consecutive medical records of patients diagnosed with PCME after uneventful cataract surgery were included. The outcomes measured included best corrected visual acuity (BCVA) and central foveal thickness (CFT). Linear regression analysis was statistically applied. Results Following topical treatment, nondiabetic and diabetic subjects presented a mean ± SD gain of − 0.11 ± 0.11 and − 0.18 ± 0.11 BCVA logMAR and a CFT reduction of − 43.42 ± 53.66 µm and − 58.76 ± 36.28 µm, respectively. The mean BCVA gain at month 12 subsequent to DEX implantation was − 0.35 ± 0.17 in nondiabetic (p
- Published
- 2023
- Full Text
- View/download PDF